_1777294237270_124456903.png&w=64&q=75){kind=small}
Avlon Pharma secures licensing deal for product in Kingdom
Avlon Pharma announced that it has signed an exclusive licensing agreement with Wun Sourse for Specialized Medicines to register and market the drug Terzipadaide in Saudi Arabia and several countries across the Middle East and North Africa. The agreement includes the right to use the Indian registration dossier for the medication in doses ranging from 2.5 to 15 mg, delivered via a multi-dose pen device. The contract duration is ten years from the launch date, with the possibility of renewal. The company expects the drug to generate cumulative revenues of more than 800 million SAR within the first five years of its launch, and the value of the agreement accounts for less than 5% of its total annual revenues. This move is part of the company's strategy to strengthen its product portfolio and expand its regional presence in the treatment of diabetes and metabolic diseases.
Notice: This Is an AI-Generated Summary
Comments (0)